


HUHS015

Cat. No.:	HY-100199
CAS No.:	1453097-13-6
Molecular Formula:	C ₁₉ H ₁₈ N ₄ O
Molecular Weight:	318.37
Target:	Others
Pathway:	Others
Storage:	<div>Powder</div> <div>-20°C 3 years</div> <div>4°C 2 years</div> <div>In solvent</div> <div>-80°C 2 years</div> <div>-20°C 1 year</div>



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 34 mg/mL (106.79 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		3.1410 mL	15.7050 mL	31.4100 mL
	5 mM		0.6282 mL	3.1410 mL	6.2820 mL
	10 mM		0.3141 mL	1.5705 mL	3.1410 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 50% PEG300 >> 50% saline
Solubility: 5 mg/mL (15.70 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (7.85 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.85 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	HUHS015 is a potent prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitor with an IC ₅₀ of 0.67 μM for PCA-1 ^[1] .
IC ₅₀ & Target	IC ₅₀ : 0.67 μM (PCA-1) ^[1]
In Vitro	HUHS015 significantly suppresses the growth of DU145 cells, which are human hormone-independent prostate cancer cells ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

HUHS015 potently suppresses the growth of DU145 cells in a mouse xenograft model^[1].

HUHS015 displays 7.2% bioavailability (BA) in rats after oral administration^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice ^[1]
Dosage:	32 mg/kg
Administration:	Subcutaneous injection; daily; 6 days
Result:	Has inhibitory effect on the growth of subcutaneously implanted DU145, without limiting weight gains after a 6 days continuous administration.

REFERENCES

[1]. Nakao S et al. Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs. Bioorg Med Chem Lett, 2014 Feb 15, 24(4):1071-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA